Jim Beach
Geschäftsführer bei Camargo Pharmaceutical Services LLC
Aktive Positionen von Jim Beach
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Camargo Pharmaceutical Services LLC
 Camargo Pharmaceutical Services LLC Miscellaneous Commercial ServicesCommercial Services Camargo Pharmaceutical Services LLC provides contract drug development, formulation, testing and regulatory consulting services. The company was founded by Kenneth V. Phelps and Ruth E. Stevens in 2003 and is headquartered in Cincinnati, OH. | Geschäftsführer | 20.11.2013 | - |
Bexion Pharmaceuticals, Inc.
 Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Geschäftsführer | - | - |
Karriereverlauf von Jim Beach
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Chief Operating Officer | 2 |
Sektoral
| Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Camargo Pharmaceutical Services LLC
Camargo Pharmaceutical Services LLC Miscellaneous Commercial ServicesCommercial Services Camargo Pharmaceutical Services LLC provides contract drug development, formulation, testing and regulatory consulting services. The company was founded by Kenneth V. Phelps and Ruth E. Stevens in 2003 and is headquartered in Cincinnati, OH. | Commercial Services |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Commercial Services |
